Girard Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Girard Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$5K	–	506
2018 Q3	$5K	Buy	+100	New	+$4.7K	﹤0.01%	835

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Girard Partners's IONS Position: Q4 2018 in Review

Girard Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2018, closing a stake of 100 shares — an estimated $5K sold.

Girard Partners first reported a position in IONS in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 329 funds tracked by Wall St. Rank hold IONS as of Q4 2018.

Girard Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 100 Ionis Pharmaceuticals shares in Q4 2018, an estimated $5K.
Girard Partners first reported a position in Ionis Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Girard Partners's Ionis Pharmaceuticals position peaked at $5K in Q3 2018.
329 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.